Jacob Simmonds MD (Res) , Steven D. Zangwill MD , Bethany Wisotzkey MD , Ryan Cantor PhD , Hong Zhao PhD , James K. Kirklin MD , Dipankar Gupta MD
{"title":"Mechanical circulatory support early after pediatric heart transplantation—an analysis from the Pediatric Heart Transplant Society","authors":"Jacob Simmonds MD (Res) , Steven D. Zangwill MD , Bethany Wisotzkey MD , Ryan Cantor PhD , Hong Zhao PhD , James K. Kirklin MD , Dipankar Gupta MD","doi":"10.1016/j.healun.2024.09.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The use of early mechanical circulatory support (MCS) following pediatric heart transplantation is not well-published. This paper attempts to uncover the incidence, predisposing factors, and outcomes of MCS in a large, international cohort.</div></div><div><h3>Methods</h3><div>The Pediatric Heart Transplant Society Database (an international, prospective, event-driven database) was retrospectively analyzed for all cases of primary heart transplant over an 11-year period (2010-2020), dividing the cohort based on need for MCS within 30 days of transplantation.</div></div><div><h3>Results</h3><div>Of 4,321 primary transplants, 249 (5.8%) required MCS (230 ECMO (Extracoporeal Membranous Oxygenation), 19 ventricular assist device). In a Cox proportional hazard model, congenital heart disease (<em>p</em> = 0.0002), older donor age (<em>p</em> < 0.0001), and longer ischemic time (<em>p</em> = 0.018) were each related to an increased need for MCS; increasing recipient body surface area (<em>p</em> < 0.0001) and increasing donor left ventricular ejection fraction (<em>p</em> = 0.016) were both correlated with less MCS use. One-year survival in those requiring MCS was 54.2%, compared with 94.8% in those who did not need MCS (<em>p</em> < 0.0001). Later survival in patients surviving to 1 year was similar between the groups.</div></div><div><h3>Conclusions</h3><div>MCS is used infrequently following pediatric heart transplant and is related to donor, recipient, and transplant factors. Although mortality is high, those surviving the first year post transplant have excellent outcomes. Judicious use in those patients who would otherwise perish is therefore justified.</div></div>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"44 2","pages":"Pages 227-233"},"PeriodicalIF":6.4000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Heart and Lung Transplantation","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1053249824018333","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background
The use of early mechanical circulatory support (MCS) following pediatric heart transplantation is not well-published. This paper attempts to uncover the incidence, predisposing factors, and outcomes of MCS in a large, international cohort.
Methods
The Pediatric Heart Transplant Society Database (an international, prospective, event-driven database) was retrospectively analyzed for all cases of primary heart transplant over an 11-year period (2010-2020), dividing the cohort based on need for MCS within 30 days of transplantation.
Results
Of 4,321 primary transplants, 249 (5.8%) required MCS (230 ECMO (Extracoporeal Membranous Oxygenation), 19 ventricular assist device). In a Cox proportional hazard model, congenital heart disease (p = 0.0002), older donor age (p < 0.0001), and longer ischemic time (p = 0.018) were each related to an increased need for MCS; increasing recipient body surface area (p < 0.0001) and increasing donor left ventricular ejection fraction (p = 0.016) were both correlated with less MCS use. One-year survival in those requiring MCS was 54.2%, compared with 94.8% in those who did not need MCS (p < 0.0001). Later survival in patients surviving to 1 year was similar between the groups.
Conclusions
MCS is used infrequently following pediatric heart transplant and is related to donor, recipient, and transplant factors. Although mortality is high, those surviving the first year post transplant have excellent outcomes. Judicious use in those patients who would otherwise perish is therefore justified.
期刊介绍:
The Journal of Heart and Lung Transplantation, the official publication of the International Society for Heart and Lung Transplantation, brings readers essential scholarly and timely information in the field of cardio-pulmonary transplantation, mechanical and biological support of the failing heart, advanced lung disease (including pulmonary vascular disease) and cell replacement therapy. Importantly, the journal also serves as a medium of communication of pre-clinical sciences in all these rapidly expanding areas.